Cell line · CVCL_2142
Papers60
1 to 20 of 60
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| Hypoxic Preconditioning Restores NK Cell Metabolic Fitness by Attenuating MAPK Signaling to Potentiate Antitumor Immunity in Lung Cancer | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| A metabolic-oxidative axis contributes to NK cell cryo-vulnerability. | iScience | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Bioprinted Tumor Microenvironment Models Reveal Immune Evasion and Guide CAR-NK Therapeutic Strategies. | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| A fully human pan VL9 HLA-E TCRm antibody enables functional dissection of HLA-E biology and checkpoint signaling. | iScience | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Radiation-induced MYB reduction unleashes TIM-3 expression in NK cells to attenuate antitumor immunity in colorectal cancer. | J Transl Med | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Combining lenalidomide with IL-2 family of cytokines enhances activating receptor and perforin/granzyme expression in NK cells. | PLoS One | 2026 | Its Methods give the RRID and name the line | PubMed | |
| The p53 tumor suppressor modulates the expression of proteins that control natural killer cell activity. | Cell Commun Signal | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Orosomucoid 2 promotes colorectal cancer liver metastasis by suppressing natural killer cell-mediated antitumor immunity by remodeling the serine and one-carbon metabolism pathway. | Mol Cancer | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Multiomics Profiling of T-cell Leukemia and Lymphoma Enables Targeted Therapeutic Discovery. | Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Chronic ER Stress Triggers Cell-Surface Chaperones as the Therapeutic Targets of CAR Cells in Acute Myeloid Leukemia. | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Macrophage-Engaging IgG4 Antibody Triggers Cytotoxicity against Integrin αvβ3+ Cancers. | Mol Cancer Ther | 2026 | Its Methods give the RRID and name the line | PubMed | |
| An immunometabolic prodrug strategy overcomes DHODH inhibitor resistance in refractory melanoma. | J Exp Clin Cancer Res | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Anti-FAP CAR-NK cells as a novel targeted therapy against cervical cancer and cancer-associated fibroblasts. | Oncoimmunology | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Effectorless Fc-fusion improves FLT3L drug-like properties for cancer immunotherapy combinations. | EBioMedicine | 2025 | Its Methods give the RRID and name the line | PubMed | |
| The puzzling regulation of the interferon signaling system by the p53 tumor suppressor protein. | Cell Mol Life Sci | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Chimeric antigen receptor NK-92 cell function is modulated by HLA class I expression of target cells. | iScience | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Ammonia Suppresses the Antitumor Activity of Natural Killer Cells and T Cells by Decreasing Mature Perforin. | Cancer Res | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Non-destructive in situ monitoring of structural changes of 3D tumor spheroids during the formation, migration, and fusion process. | Elife | 2025 | Its Methods give the RRID and name the line | PubMed | |
| The FcγRIIIA (CD16) L48-H/R Polymorphism Enhances NK Cell-Mediated Antibody-Dependent Cellular Cytotoxicity by Promoting Serial Killing. | Cancer Immunol Res | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Interleukin-2-mediated NF-κB-dependent mRNA splicing modulates interferon gamma protein production. | EMBO Rep | 2025 | Its Methods give the RRID and name the line | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_2142/papers